InterCloud Systems, Inc. (NASDAQ:ICLD) shares moved down -0.72% in last trading session and ended the day at $1.37. ICLD Gross Margin is 28.10% and its has a return on assets of -37.40%. InterCloud Systems, Inc. (NASDAQ:ICLD) quarterly performance is -21.71%.
InterCloud Systems (NASDAQ: ICLD) announced that it was recently awarded over $2.3 million in new contracts. The company said, “revenue is up 23% to $65 Million through Q-3 2015.”
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) ended the last trading day at $18.25. Company weekly volatility is calculated as 118.33% and price to cash ratio as 3.27. KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) showed a weekly performance of 1927.78%.
KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Mr. Shkreli regarding possible direction for the company to continue in operation. Mr. Shkreli is the founder and chief executive officer of Turing Pharmaceuticals, a privately held biopharmaceutical company.
Goodrich Petroleum (NYSE:GDP) was downgraded by Zacks from a “buy” rating to a “hold” rating in a report issued on Tuesday, Market Beat Ratings reports.
On 20 November, Goodrich Petroleum Corp. (NYSE:GDP) shares decreased -6.12% and was closed at $0.46. GDP EPS growth in last 5 year was -3.80%. Goodrich Petroleum Corp. (NYSE:GDP) year to date (YTD) performance is -89.64%.
Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) shares moved up 0.94% in last trading session and ended the day at $2.15. ATNM has a return on assets of -100.80%. Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) quarterly performance is 12.57%.
ON 17 November, Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). Pending the FDA’s acceptance of the IND filing, Actinium will initiate a single, pivotal Phase 3 clinical study in refractory and relapsed AML patients over the age 55.
FBL Financial Group Inc. (NYSE:FFG) caters to the Financial space. It has a net profit margin of 15.40% and weekly performance is 4.78%. On the last day of trading company shares ended up at $67.46. FBL Financial Group Inc. (NYSE:FFG) distance from 50-day simple moving average (SMA50) is 8.66%.
FBL Financial Group, Inc. (NSYE:FFG) announced that its Board of Directors declared a quarterly cash dividend of $0.40 per share to owners of Class A and Class B common stock. The dividend will be payable on December 31, 2015 to shareholders of record as of December 15, 2015. There are currently 24,786,810 shares of Class A common stock and 11,413 shares of Class B common stock outstanding, for a total of 24,798,223 shares outstanding.